论文部分内容阅读
目的观察和评价化疗并用微卡治疗耐多药肺结核的疗效。方法将患者随机分为微卡加化疗治疗组与单纯化疗观察组 ,观察治疗后肺部病灶吸收 ,痰菌阴转情况。结果 3个月末痰菌阴转率 :治疗组与观察组分别为 5 5 .6%和 2 5 .7% ,疗程结束痰菌阴转率分别为77.8%和 48.6%。治疗组显著高于观察组 (P<0 .0 1)。治疗组与观察组疗程结束肺部病灶吸收好转率分别为 83 .3 %和 5 4.3 % ;空洞闭合率分别为 73 .4%和 45 .5 % ,治疗组显著高于观察组 (P<0 .0 1)。结论微卡能提高痰菌阴转率 ,有助于病灶吸收 ,可作为耐多药肺结核的免疫治疗和化疗的辅助治疗
Objective To observe and evaluate the efficacy of chemotherapy and micro-card in the treatment of multidrug-resistant pulmonary tuberculosis. Methods The patients were randomly divided into micro-card plus chemotherapy group and chemotherapy alone observation group to observe the absorption of lung lesions after treatment, sputum negative conversion. Results At the end of 3 months, the sputum negative conversion rate was 55.6% and 25.7% in the treatment group and the observation group respectively. The sputum negative conversion rates at the end of the treatment were 77.8% and 48.6%, respectively. The treatment group was significantly higher than the observation group (P <0.01). In the treatment group and the observation group, the improvement rate of lung lesion absorption rate was 83.3% and 53.3% respectively; the void closure rates were 73.4% and 45.5% respectively, and the treatment group was significantly higher than the observation group (P <0. .0 1). Conclusion Micro-card can improve the sputum negative conversion rate, which can help the absorption of the lesion, and can be used as an adjuvant therapy for immunotherapy and chemotherapy resistant to multi-drug pulmonary tuberculosis